A study in the Journal of the American Medical Association found that transgender people who give birth are more likely to have lasting health problems than biological women who give birth.
The FDA analysts also raised concerns about whether women with medical conditions that should preclude them from taking the pill, primarily breast cancer and undiagnosed vaginal bleeding, would avoid the product.
The court ordered "that the trial court shall forthwith conduct such proceedings as appropriate to resolve" the signature verification allegations raised by Lake.
